Development and Content Validity Evaluation of the Condition-Agnostic Treatment Goal Evaluation Scale (TGES) for Use in Chronic Conditions.

IF 2.4 Q3 HEALTH CARE SCIENCES & SERVICES
Patient Related Outcome Measures Pub Date : 2026-01-27 eCollection Date: 2025-01-01 DOI:10.2147/PROM.S558968
Jonathan Stokes, Katie D Stewart, Jessica B Jordan, Louis S Matza, Somali Misra Burgess, David L Van Brunt, Jessica E Hutti
{"title":"Development and Content Validity Evaluation of the Condition-Agnostic Treatment Goal Evaluation Scale (TGES) for Use in Chronic Conditions.","authors":"Jonathan Stokes, Katie D Stewart, Jessica B Jordan, Louis S Matza, Somali Misra Burgess, David L Van Brunt, Jessica E Hutti","doi":"10.2147/PROM.S558968","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Patient-reported outcomes (PROs) are important for understanding patients' experiences with their health conditions; however, individual perspectives of meaningful change for personalized treatment goals are rarely captured. Consequently, treatment outcomes assessed in clinical trials or routine practice may not align with real-world priorities or reflect individual perspectives. To bridge this gap, we developed the 2-part treatment goal evaluation scale (TGES) to assess individuals' perspectives of whether meaningful within-patient change has occurred in their self-identified treatment goal.</p><p><strong>Methodology: </strong>The draft TGES measure included the TGES - Baseline-a single, open-ended item to identify patients' primary treatment goal when starting a new treatment for a new or ongoing condition-and the TGES - Follow-Up-2 items designed to assess patients' perspectives of whether meaningful change has occurred in their self-identified goal and overall condition. Three rounds of qualitative interviews with adults aged ≥18 years with either atopic dermatitis (AD) or migraine were conducted to revise the draft TGES and assess content validity.</p><p><strong>Results: </strong>A total of 28 participants with AD (n=15) or migraine (n=13) were included; most identified as female (60.7%) and White (78.6%). Most participants interpreted the TGES - Baseline instructions (82.1%) and item (96.4%) as intended, whereas 39.3% suggested revisions to the instructions. Overall goal categories were identified: 3 AD-specific (improving physical symptoms, sensory symptoms, and choice of clothing) and 4 migraine-specific (reduced migraine frequency, impact on activities, migraine severity, and associated symptoms other than headache). Most participants interpreted the TGES - Follow-Up instructions (100.0%) and items (96.4%; 75.0%) as intended, with minor revisions suggested to improve clarity.</p><p><strong>Conclusion: </strong>Qualitative interviews supported the content validity of the TGES for identifying individual treatment goals and assessing perspectives of meaningful change. With future quantitative evaluation, the patient-centric and condition-agnostic TGES may help evaluate personalized endpoints and inform within-patient meaningful change in clinical trial and real-world settings.</p>","PeriodicalId":19747,"journal":{"name":"Patient Related Outcome Measures","volume":"16 ","pages":"558968"},"PeriodicalIF":2.4000,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13077846/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Patient Related Outcome Measures","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/PROM.S558968","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEALTH CARE SCIENCES & SERVICES","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Patient-reported outcomes (PROs) are important for understanding patients' experiences with their health conditions; however, individual perspectives of meaningful change for personalized treatment goals are rarely captured. Consequently, treatment outcomes assessed in clinical trials or routine practice may not align with real-world priorities or reflect individual perspectives. To bridge this gap, we developed the 2-part treatment goal evaluation scale (TGES) to assess individuals' perspectives of whether meaningful within-patient change has occurred in their self-identified treatment goal.

Methodology: The draft TGES measure included the TGES - Baseline-a single, open-ended item to identify patients' primary treatment goal when starting a new treatment for a new or ongoing condition-and the TGES - Follow-Up-2 items designed to assess patients' perspectives of whether meaningful change has occurred in their self-identified goal and overall condition. Three rounds of qualitative interviews with adults aged ≥18 years with either atopic dermatitis (AD) or migraine were conducted to revise the draft TGES and assess content validity.

Results: A total of 28 participants with AD (n=15) or migraine (n=13) were included; most identified as female (60.7%) and White (78.6%). Most participants interpreted the TGES - Baseline instructions (82.1%) and item (96.4%) as intended, whereas 39.3% suggested revisions to the instructions. Overall goal categories were identified: 3 AD-specific (improving physical symptoms, sensory symptoms, and choice of clothing) and 4 migraine-specific (reduced migraine frequency, impact on activities, migraine severity, and associated symptoms other than headache). Most participants interpreted the TGES - Follow-Up instructions (100.0%) and items (96.4%; 75.0%) as intended, with minor revisions suggested to improve clarity.

Conclusion: Qualitative interviews supported the content validity of the TGES for identifying individual treatment goals and assessing perspectives of meaningful change. With future quantitative evaluation, the patient-centric and condition-agnostic TGES may help evaluate personalized endpoints and inform within-patient meaningful change in clinical trial and real-world settings.

慢性疾病不可知治疗目标评价量表(TGES)的编制及内容效度评价
背景:患者报告的结局(PROs)对于了解患者的健康状况非常重要;然而,对个性化治疗目标有意义的改变的个人观点很少被捕获。因此,临床试验或常规实践评估的治疗结果可能与现实世界的优先事项不一致或反映个人观点。为了弥补这一差距,我们开发了两部分治疗目标评估量表(TGES),以评估个体对其自我确定的治疗目标是否发生了有意义的患者内部变化的看法。方法:TGES措施草案包括TGES -基线-一个单一的开放式项目,用于确定患者在开始新的或持续的疾病的新治疗时的主要治疗目标-以及TGES -随访-2项目,旨在评估患者对其自我确定的目标和总体状况是否发生了有意义的变化的看法。对年龄≥18岁的特应性皮炎(AD)或偏头痛患者进行了三轮定性访谈,以修订TGES草案并评估内容效度。结果:共有28名AD患者(n=15)或偏头痛患者(n=13)被纳入;大多数是女性(60.7%)和白人(78.6%)。大多数参与者对TGES -基线说明(82.1%)和项目(96.4%)的解释是预期的,而39.3%的参与者建议对说明进行修改。确定了总体目标类别:3个ad特异性(改善身体症状、感觉症状和服装选择)和4个偏头痛特异性(减少偏头痛频率、对活动的影响、偏头痛严重程度和头痛以外的相关症状)。大多数参与者按照预期解释了TGES -随访说明(100.0%)和项目(96.4%;75.0%),并建议进行少量修改以提高清晰度。结论:质性访谈支持TGES在确定个体治疗目标和评估有意义改变角度方面的内容效度。在未来的定量评估中,以患者为中心和病情不可知的TGES可能有助于评估个性化终点,并在临床试验和现实环境中告知患者有意义的变化。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Patient Related Outcome Measures
Patient Related Outcome Measures HEALTH CARE SCIENCES & SERVICES-
自引率
4.80%
发文量
27
审稿时长
16 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书